Treatment of Uncomplicated Hypertension: Are ACE Inhibitors and Calcium Channel Blockers as Effective as Diuretics and β-Blockers?

References

1. ↵
   The sixth report of Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–46.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1999 Heart and stroke statistical update. Dallas: American Heart Association, 1998.
3. ↵
   The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154–83.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255–64.

   OpenUrlCrossRefPubMedWeb of Science
5. Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–85.

   OpenUrlCrossRefPubMedWeb of Science
6. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992; 304: 405–12.
7. ↵
   Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension 2000; 36: 600–3.

   OpenUrlAbstract/FREE Full Text
8. ↵
   Knight EL, Glynn RJ, Levin R, Ganz DA, Avorn J. Failure of evidence-based medicine in the treatment of hypertension in older patients. J Gen Intern Med 2000; 15: 702–9.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    Hansson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999; 354: 1751–6.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    Hansson L, Hedner T, Lund-Johansen P, et al. Randomized trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–65.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914–21.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    Grimm RH Jr, Grandits GA, Cutler JA, et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med 1997; 157: 638–48.

    OpenUrlCrossRefPubMedWeb of Science
15. Hansson L, Hedner T, Lindholm L, et al. The Captopril Prevention Project (CAPPP) in hypertension–baseline data and current status. Blood Press 1997; 6: 365–7.

    OpenUrlPubMed
16. ↵
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–62.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    Ramsey SD, Neil N, Sullivan SD, Perfetto E. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. J Am Board Fam Pract 1999; 12: 105–14.

    OpenUrlAbstract/FREE Full Text
18. ↵
    Cost effectiveness of intensive treatment of hypertension. Am J Manag Care 1998; 4(12 Suppl): S765–69.

    OpenUrlPubMed
19. ↵
    1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee J Hypertens 1999; 17: 151–83.

    OpenUrl
20. ↵
    Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996; 9(4 Pt 1): 342–60.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283: 1967–75.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949–54.

    OpenUrlCrossRefPubMedWeb of Science
24. ↵
    Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.

    OpenUrlAbstract/FREE Full Text
25. ↵
    Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardio vascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645–52.

    OpenUrlCrossRefPubMedWeb of Science
26. ↵
    Black HR, Elliott WJ, Neaton JD, et al. Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial. Control Clin Trials 1998; 19: 370–90.

    OpenUrlCrossRefPubMedWeb of Science
27. ↵
    Siegal D, Lopez J. Trends in antihypertensive drug use in the United States - do the JNC V recommendations affect prescribing? Fifth Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 1997; 278: 1745–8.

    OpenUrlCrossRefPubMedWeb of Science
28. ↵
    Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There is no such thing as a free lunch. Chest 1992; 102: 270–3.

    OpenUrlCrossRefPubMedWeb of Science
29. Chew LD, O’Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A physician survey of the effect of drug sample availability on physicians’ behavior. J Gen Intern Med 2000; 15: 478–83.

    OpenUrlCrossRefPubMedWeb of Science
30. Chren MM, Landefeld CS. Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994; 271: 684–9.

    OpenUrlCrossRefPubMedWeb of Science
31. ↵
    Ubel PA, Adler MA. Primary care physicians believe that calcium blockers and ACE inhibitors are superior to beta-blockers and diuretics in treating uncomplicated hypertension. J Gen Intern Med 1999; 14(Suppl 2): 125.